AWMSG issues Final Appraisal Recommendation on bortezomib (Velcade®) subcutaneous injection

Source: All Wales Medicines Strategy Group (AWMSG) Area: Evidence > Drug Specific Reviews In its Final Appraisal Recommendation, the All Wales Medicines Strategy Group (AWMSG) is of the opinion that bortezomib (Velcade®) 3.5 mg subcutaneous injection is appropriate for specialist only prescribing within NHS Wales, as an alternative to the intravenous injection, for the following indications:   . treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.   . in combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news